The research Of novel coronavirus pneumonia (COVID-19) patients' immune status and severity of disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000033190

Enrollment

Unknown

Registered

2020-05-23

Start date

2020-03-01

Completion date

Unknown

Last updated

2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

A?B?C:Human immunoglobulin group (a), Xuebijing group (b), and human immunoglobulin group + Xuebijing group (c).

Eligibility

Sex/Gender

All

Age

17 Years to 71 Years

Inclusion criteria

Inclusion criteria: The novel coronavirus pneumonia diagnosis and treatment plan was included in 180 cases of 2019-nCoV pneumonia in our hospital (accord with the National Health Protection Committee's new crown pneumonia diagnostic scheme). The definition of confirmed cases in the Fifth Edition) excludes HIV and other immunodeficiency diseases from the included cases, and classifies the severity of the included clinical cases into light and common Type C, heavy duty 3 groups. Meanwhile, 30 healthy volunteers of the same age at the same time were recruited as the control group and the case data and blood samples of patients diagnosed with 2019 ncov pneumonia Data of patients with 2019 ncov pneumonia were collected and processed through the medical record system.

Exclusion criteria

Exclusion criteria: HIV and other immunodeficiency diseases

Design outcomes

Primary

Measure	Time frame
Immune intervention effect;	—

Countries

China

Contacts

Public ContactYuanlin Xie

The First Hospital of Changsha

ailianlv@sina.com+86 13975137399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026